Pharmacokinetic Interactions Between Gemigliptin and Metformin, and Potential Differences in the Pharmacokinetic Profile of Gemigliptin Between the Mexican and Korean Populations: A Randomized, Open-label Study in Healthy Mexican Volunteers.
Sign Up to like & getrecommendations! Published in 2018 at "Clinical therapeutics"
DOI: 10.1016/j.clinthera.2018.08.015
Abstract: PURPOSE The aim of this study was to assess the pharmacokinetic interactions between a newly developed dipeptidyl peptidase (DPP)-4 inhibitor, gemigliptin, and metformin in healthy Mexican male volunteers, and the differences in the pharmacokinetic profile… read more here.
Keywords: gemigliptin metformin; pharmacokinetic profile; gemigliptin; profile gemigliptin ... See more keywords
Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40‐week extension of the GUARD randomized study
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes"
DOI: 10.1111/dom.13059
Abstract: The long‐term safety and efficacy of gemigliptin was evaluated in the present extension study after a 12‐week study during a 40‐week follow‐up period. read more here.
Keywords: week; safety; study; efficacy ... See more keywords
Gemigliptin Inhibits IL-1ß–Induced Endothelial-Mesenchymal Transition via BMP2/Smad/MAPK/Runx2 Pathway
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes"
DOI: 10.2337/db18-477-p
Abstract: Objective: Endothelial-to-mesenchymal transition (EndMT) contributes to inflammatory conditions inducing conversion of endothelial cells (ECs) into activated fibroblasts, promoting fibrotic diseases. Pro-inflammatory cytokine interleukin (IL)-1s is the most potent inducer of EndMT. We investigated inhibition of… read more here.
Keywords: mesenchymal transition; bmp; endothelial mesenchymal; smad ... See more keywords
Pharmacokinetic Equivalence of the High Dose Strength Fixed-Dose Combination Tablet of Gemigliptin/Metformin Sustained Release (SR) and Individual Component Gemigliptin and Metformin XR Tablets in Healthy Subjects
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Korean Medical Science"
DOI: 10.3346/jkms.2018.33.e258
Abstract: Background In type 2 diabetes mellitus therapy, fixed-dose combination (FDC) can offer not only benefits in glucose control via the combined use of agents, but also increase patient compliance. The aim of this study was… read more here.
Keywords: gemigliptin metformin; gemigliptin; tablet gemigliptin; pharmacokinetic equivalence ... See more keywords
Efficacy and Safety of the Novel Dipeptidyl Peptidase-4 Inhibitor Gemigliptin in the Management of Type 2 Diabetes: A Meta-Analysis
Sign Up to like & getrecommendations! Published in 2021 at "Endocrinology and Metabolism"
DOI: 10.3803/enm.2020.818
Abstract: Background No meta-analysis has holistically analysed and summarised the efficacy and safety of gemigliptin in type 2 diabetes. The meta-analysis addresses this knowledge gap. Methods Electronic databases were searched for randomised controlled trials (RCTs) involving… read more here.
Keywords: efficacy safety; type diabetes; gemigliptin; meta analysis ... See more keywords
Gemigliptin Alleviates Succinate-Induced Hepatic Stellate Cell Activation by Ameliorating Mitochondrial Dysfunction
Sign Up to like & getrecommendations! Published in 2022 at "Endocrinology and Metabolism"
DOI: 10.3803/enm.2022.1530
Abstract: Background Dipeptidyl peptidase-4 inhibitors (DPP-4Is) are used clinically as oral antidiabetic agents. Although DPP-4Is are known to ameliorate liver fibrosis, the protective mechanism of DPP-4Is in liver fibrosis remains obscure. In this study, gemigliptin was… read more here.
Keywords: mitochondrial dysfunction; dpp 4is; liver fibrosis; gemigliptin ... See more keywords